Is It Safe To Switch Oac In Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention? Results From A Re-Dual Pci Subanalysis

Jurriën M. ten Berg,Anne J.W.M. de Veer,Jonas Oldgren,Philippe Gabriel Steg,Dmitry Aleksandrovich Zateyshchikov,Petr Janský,Ki-Bae Seung,Stefan H. Hohnloser,Gregory Y.H. Lip,Matias Nordaby,Eva Kleine,Deepak L. Bhatt,Christopher P. Cannon

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY（2018）

引用 1|浏览13

暂无评分

摘要

The RE-DUAL PCI trial showed that bleeding risk was lower with dabigatran dual vs. warfarin triple therapy in patients with nonvalvular atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI). We studied whether this lower bleeding risk was also present in patients who were long

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要